Skip to main content
Premium Trial:

Request an Annual Quote

Checks and Balances for Journals

Kay blogs at Suicyte Notes about the age-old dilemma of peer review: keeping reviewers anonymous to allow them to say whatever they want, while making them accountable to the scientists whose papers are at stake. Kay says that while she considers reviewer anonymity to be "essential for giving me the freedom of saying things that have to be said," she does feel that there should be a formal avenue of complaint for scientists who think reviewers have been unfair. This avenue would give authors "the possibility to do something about reviewer reports that are way off the mark, be it due to hostility, incompetence, or laziness."

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.